Company research / APVO

Aptevo Therapeutics Inc. (APVO)

CIK 0001671584 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

Partial revenue. In this company's filings, net income for the year ended 2022-12-31 is larger than reported revenue. The revenue it tags covers only part of its income (banks and REITs often tag only fee income this way, leaving out interest or rent), so it is not the company's whole top line. Margins on it are not computed, and it is left out of revenue rankings.

Key ratios (year ended 2025-12-31)

-149.4%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-14

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-44, first reflected in a filing dated 2024-05-08; 1-for-18, first reflected in a filing dated 2026-03-26. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenuen/an/an/an/a$3.11M$12.29M$4.31M$32.42M$23.07M$14.66M$9.98M
Cost of Revenuen/an/an/an/an/an/an/a$19.93M$11.21Mn/an/a
Gross Profit (computed)n/an/an/an/an/an/an/a$12.50M$11.85Mn/an/a
R&D Expense$15.20M$14.54M$14.38M$17.11M$17.88M$18.99M$17.85M$24.76M$35.38M$29.02M$29.12M
Operating Income-$26.89M-$26.31M-$24.60M-$28.88M-$28.64M-$21.40M-$27.49M-$40.96M-$51.66M-$53.95M-$138.77M
Depreciation & Amortization$197.0K$240.0K$352.0K$567.0K$901.0K$1.14M$1.41M$2.23M$2.39M$3.13M$3.36M
EBITDA-$26.69M-$26.07M-$24.25M-$28.31M-$27.74M-$20.26M-$26.09M-$38.73M-$49.27M-$50.82M-$135.41M
Net Income-$26.41M-$25.97M-$24.13M-$17.41M$8.03M-$28.46M-$17.75M-$40.45M-$53.69M$6.97M-$112.42M
EPS (Diluted)n/a-$87.27-$31460.23-$2316.83$1.57-$6.07n/an/an/an/an/a
Total Assets$14.52M$27.19M$15.59M$24.84M$34.22M$56.60M$53.55M$53.41M$67.49M$117.01M$91.86M
Total Liabilities$8.48M$9.81M$10.84M$12.62M$16.24M$55.38M$36.95M$41.57M$37.09M$34.97M$41.29M
Long-Term Debtn/an/an/a$0$4.01M$16.02M$28.22Mn/an/an/an/a
Shareholders' Equity$6.04M$17.38M$4.75M$12.22M$17.97M$1.22M$16.59M$11.84M$30.41M$82.03M$50.57M
Cash & Equivalents$9.80M$21.62M$8.71M$16.90M$22.64M$45.04M$39.98M$12.45M$30.64M$7.09M$9.68M
Operating Cash Flow-$25.34M-$25.59M-$23.79M-$11.73M-$21.02M-$21.68M-$29.32M-$42.38M-$51.42M-$41.57M-$36.86M
Capital Expendituresn/an/an/an/a$29.0K$713.0K$88.0K$153.0K$976.0K$1.40M$2.51M
Free Cash Flown/an/an/an/a-$21.05M-$22.39M-$29.41M-$42.54M-$52.40M-$42.98M-$39.37M
Shares Outstanding1.42M997.8K4.1K12.0K6.47M4.90M4.41M3.23M22.81M21.61M20.27M
Weighted Average Diluted Sharesn/a315.5K7677.5K5.10M4.69Mn/an/an/an/an/a
EPS (Basic)n/a-$87.27-$31460.23-$2316.83$1.57-$6.07n/an/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView